Please use this identifier to cite or link to this item:
|Title:||Angiotensin AT 1 and AT 2 receptor heteromer expression in the hemilesioned rat model of Parkinson's disease that increases with levodopa-induced dyskinesia|
|Author:||Rivas Santisteban, Rafael|
Rodríguez Pérez, Ana I.
Labandeira García, José L.
Navarro Brugal, Gemma
Franco Fernández, Rafael
Malaltia de Parkinson
|Abstract:||Background/aims: The renin-angiotensin system (RAS) is altered in Parkinson's disease (PD), a disease due to substantia nigra neurodegeneration and whose dopamine-replacement therapy, using the precursor levodopa, leads to dyskinesias as the main side effect. Angiotensin AT1 and AT2 receptors, mainly known for their role in regulating water homeostasis and blood pressure and able to form heterodimers (AT1/2Hets), are present in the central nervous system. We assessed the functionality and expression of AT1/2Hets in Parkinson disease (PD). Methods: Immunocytochemistry was used to analyze the colocalization between angiotensin receptors; bioluminescence resonance energy transfer was used to detect AT1/2Hets. Calcium and cAMP determination, MAPK activation, and label-free assays were performed to characterize signaling in homologous and heterologous systems. Proximity ligation assays were used to quantify receptor expression in mouse primary cultures and in rat striatal sections. Results: We confirmed that AT1 and AT2 receptors form AT1/2Hets that are expressed in cells of the central nervous system. AT1/2Hets are novel functional units with particular signaling properties. Importantly, the coactivation of the two receptors in the heteromer reduces the signaling output of angiotensin. Remarkably, AT1/2Hets that are expressed in both striatal neurons and microglia make possible that candesartan, the antagonist of AT1, increases the effect of AT2 receptor agonists. In addition, the level of striatal expression increased in the unilateral 6-OH-dopamine lesioned rat PD model and was markedly higher in parkinsonian-like animals that did not become dyskinetic upon levodopa chronic administration if compared with expression in those that became dyskinetic. Conclusion: The results indicate that boosting the action of neuroprotective AT2 receptors using an AT1 receptor antagonist constitutes a promising therapeutic strategy in PD. Keywords: Dyskinesia; G-protein-coupled receptor (GPCR); Heteromer; Levodopa; Neuroinflammation.|
|Note:||Reproducció del document publicat a: https://doi.org/10.1186/s12974-020-01908-z|
|It is part of:||Journal of Neuroinflammation, 2020|
|Appears in Collections:||Articles publicats en revistes (Bioquímica i Fisiologia)|
Articles publicats en revistes (Bioquímica i Biomedicina Molecular)
This item is licensed under a Creative Commons License